Effects of SPARC and Possible Receptors on Colon Cancer Cell Line

Authors : Duygu MISIRLI, Özlem BİNGÖL ÖZAKPINAR, Turgut ŞEKERLER, Başak ARU, Gülderen YANIKKAYA DEMİREL, Servet TUNOĞLU, Derya OZSAVCİ

Pages : 316-322

Doi:10.33808/clinexphealthsci.1100770

View : 73 | Download : 145

Publication Date : 2023-06-15

Article Type : Research Paper

Abstract :Objective: The aim of this study was to observe the apoptotic/cytotoxic effects of exogenous SPARC on colon cancer cell line HT-29, then to investigate the function of stabilin-1 and integrin αvβ3, which are possible receptors for SPARC in colon cancer cells and to determine the quantitation of their receptor numbers. Methods: Appropriate doses of exogenous SPARC and it’s inhibitor, cilengitide added to HT-29 cell line were determined by xCELLigence Real-Time Cell Analysis system, SPARC-mediated caspase 3 expressions were measured. Using the RT-PCR system, gene expression levels of SPARC, stabilin-1 and integrin αvβ3 receptors insert ignore into journalissuearticles values(silenced/nonsilenced with cilengitide); were detected then the numbers of receptors per cell were quantitated by flow cytometry. Results: IC50 value of SPARC was determined as 4.57 μg/mL and IC50 value of cilengitide was determined as 50 nM. 5 μg/mL exogenous SPARC caused increased apoptosis in the HT-29 line. Significant increase in gene expression of integrin αvβ3 receptor was observed in the group incubated with 5 μg/mL SPARC, contrarily, the addition of cilengitide decreased gene expressions. The integrin αvβ3 receptor numbers increased approximately 2-fold with SPARC compared to the control. No significant changes were observed in the gene expression and receptor numbers of stabilin-1. Conclusion: Exogenous SPARC was shown to reduce proliferation and induce apoptosis in colon cancer cells. Integrin αvβ3 is thought to be the possible receptor mediating SPARC in colon cancer cells. Quantification of surface receptors per cell, which we think we have done first, can be considered as a marker in the follow-up of anticancer treatments.
Keywords : SPARC, cilengitide, colon cancer, stabilin 1, integrin αvβ3